Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
In the citing paper
“In contrast to these negative regulators of insulin action, SIRT1 appears to be a positive regulator of insulin sensitivity (43,44).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [43]
In the citing paper
“Additionally, the non-naturally occurring sirtuin-activating compound, SRT1720, has enhanced insulin sensitivity and oxidative metabolism in animal models of obesity, in part, by improving mitochondrial oxidative capacity231.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [231]
In the citing paper
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218). These compounds also improve insulin sensitivity in obese rodents (218).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Self-citationTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Self-citationSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Self-citation
Research works printed but not linked: 1
- Banks A, et al. Overexpression of the Sirtuin SIRT1 increases insulin sensitivity in aging mice. Diabetes. 2007;56(S1):0234-OR. [Google Scholar]
Cited by
Items 501–600 of 1,004
Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells
Kalle, A. M., Mallika, A., Badiger, J., Nakhi, A., Talukdar, P., & Sachchidanand (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.118 · Cited by 90
Hoffmann, J., Romey, R., Fink, C., Yong, L., & Roeder, T. (2013) · Aging · doi:10.18632/aging.100553 · Cited by 83
Bruckbauer, A., & Zemel, M. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089166 · Cited by 82
“AMP-activated protein kinase (AMPK) and the sirtuins Sirt1 and Sirt3 are well-known key sensors of energy status and regulators of glucose and lipid metabolism [1–3].”
BackgroundBiological and catalytic functions of sirtuin 6 as targets for small-molecule modulators
Klein, M. A., & Denu, J. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011438 · Cited by 88
Komorowska, D., Radzik, T., Kalenik, S., & Rodacka, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810627 · Cited by 95
“The clinical trials (NCT02244879) evaluated whether an increase in SIRT-1 expression/activation affected the acetylation of histone 3 at the 56th lysine residue (H3K56ac) in T2DM patients who were receiving either resveratrol or placebo for 6 months.”
BackgroundInfluentialGuan, X., Lin, P., Knoll, E., & Chakrabarti, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107729 · Cited by 81
Du, L., Xie, J., Cheng, X., Li, X.-H., Kong, F., Jiang, X., Ma, Z., Wang, J., Chen, C., & Zhou, X. (2013) · AGE · doi:10.1007/s11357-013-9592-1 · Cited by 86
Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein
Szántó, M., Brunyánszki, A., Kiss, B., Nagy, L., Gergely, P., Virág, L., & Bai, P. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1003-8 · Cited by 94
“activators such as resveratrol [84], SIRT1720 [85], AMPK activators [86], or PARP inhibitors [87].”
BackgroundSIRT1 Contains N- and C-terminal Regions That Potentiate Deacetylase Activity
Pan, M., Yuan, H., Brent, M., Ding, E. C., & Marmorstein, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.285031 · Cited by 81
“There have also been reports of sirtuin activators including resveratrol (27) and a family of compounds unrelated to resveratrol (34), although several other reports suggest that the SIRT1 activation observed for these compounds is an artifact of the assay method used (28, 35–37).”
BackgroundZhou, X., Xu, J., Ni, Y.-H., Chen, X., Zhang, H., Zhang, X., Liu, W.-J., Luo, L., & Fu, Y. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0097-z · Cited by 86
“SRT1720, a specific activator of SIRT1, is 1000 times more potent than resveratrol [24,25].”
BackgroundMethodSirtuins: Novel targets for metabolic disease in drug development
Jiang, W. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.048 · Cited by 90
“similar changes [57].”
BackgroundValente, S., Mellini, P., Spallotta, F., Carafa, V., Nebbioso, A., Polletta, L., Carnevale, I., Saladini, S., Trisciuoglio, D., Gabellini, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01117 · Cited by 84
Chan, A., & Chen, C.-W. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00081 · Cited by 95
Chen, L.-L., Zhang, H.-H., Zheng, J., Hu, X., Kong, W., Hu, D., Wang, S.-X., & Zhang, P. (2011) · Metabolism · doi:10.1016/j.metabol.2011.04.002 · Cited by 81
“The effect of RES on peripheral IR is not unexpected, as supplementation of SRT1720, a smallmolecule but a more potent activator of SIRT1, to Zucker fa/fa rats for 4 weeks results in about 55% higher glucose disposal into skeletal muscle [12].”
BackgroundRehman, H., Krishnasamy, Y., Haque, K., Thurman, R. G., Lemasters, J. J., Schnellmann, R. G., & Zhong, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065029 · Cited by 87
Sirtuin activators: Designing molecules to extend life span
Camins, A., Sureda, F. X., Junyent, F., Verdaguer, E., Folch, J., Pelegrí, C., Vilaplana, J., Beas‐Zárate, C., & Pallàs, M. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.06.005 · Cited by 90
Mulakayala, N., Rambabu, D., Raja, M. R., Chaitanya, M., Kumar, C. S., Kalle, A. M., Krishna, G. R., Reddy, C. M., Rao, M. V. B., & Pal, M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.001 · Cited by 84
The controversial links among calorie restriction, SIRT1, and resveratrol
Hu, Y., Liu, J., Wang, J., & Liu, Q. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.034 · Cited by 93
“induced modulation of metabolic pathways [25–27].”
BackgroundResultInfluentialHormesis does not make sense except in the light of TOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100411 · Cited by 78
“Resveratrol indirectly antagonizes the mTOR/S6K pathway upstream and downstream [129, 149-153], in part via activation of AMPK and sirtuins [154-160].”
BackgroundCheang, W. S., Wong, W. T., Wang, L., Cheng, C. K., Lau, C. W., Ronald, C. W., Xu, A., Wang, N., Huang, Y., & Tian, X. Y. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.041 · Cited by 80
Moore, J., Bradshaw, E., Seipke, R. F., Hutchings, M. I., & McArthur, M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-404634-4.00018-8 · Cited by 96
Association of Sirtuin 1 (SIRT1) Gene SNPs and Transcript Expression Levels With Severe Obesity
Clark, S. J., Falchi, M., Olsson, B., Jacobson, P., Cauchi, S., Balkau, B., Marre, M., Lantieri, O., Andersson, J. C., Jernås, M., et al. (2012) · Obesity · doi:10.1038/oby.2011.200 · Cited by 79
Ljubicic, V., Burt, M., & Jasmin, B. (2014) · The FASEB Journal · doi:10.1096/fj.13-238071 · Cited by 76
“(107) first demonstrated that SRT1720 robustly stimulates SIRT1 activity in vitro, whereas chronic (i.”
BackgroundNelson, L. E., Valentine, R. J., Cacicedo, J. M., Gauthier, M.-S., Ido, Y., & Ruderman, N. B. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2011 · Cited by 79
“Acetylation status of p53 and histone H3 did not reflect SIRT1 activation; however, there is debate as to the effectiveness of this compound to directly activate SIRT1 (38, 44).”
BackgroundSirolimus and Everolimus Induce Endothelial Cellular Senescence Via Sirtuin 1 Down-Regulation
Ota, H., Eto, M., Ako, J., Ogawa, S., Iijima, K., Akishita, M., & Ouchi, Y. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.072 · Cited by 84
Current and Future Drug Targets in Weight Management
Witkamp, R. F. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0341-1 · Cited by 91
“17) have been synthesized with structures different from that of resveratrol but with considerably higher potency (159,160).”
BackgroundAntiaging effects of bioactive molecules isolated from plants and fungi
Martel, J., Ojcius, D. M., Ko, Y., Chang, C., & Young, J. D. (2019) · Medicinal Research Reviews · doi:10.1002/med.21559 · Cited by 81
“Sirtuin‐activating compounds (STACs) have been developed and these have been described to be 1000 times more active than resveratrol at activating SIRT1.(172) One of these molecules, called SRT1720 [22], extends mean and maximum lifespan in HFD‐fed mice and is associated with improved insulin sensitivity, locomotor ac…”
BackgroundYang, J., Kong, X., Martins-Santos, M. E. S., Aleman, G., Chaco, E., Liu, G. E., Wu, S.-Y., Samols, D., Hakimi, P., Chiang, C.-M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047340 · Cited by 78
Role of nutraceutical SIRT1 modulators in AMPK and mTOR pathway: Evidence of a synergistic effect
Giovannini, L., & Bianchi, S. E. (2016) · Nutrition · doi:10.1016/j.nut.2016.09.008 · Cited by 82
SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol
Fullerton, M. D., & Steinberg, G. R. (2010) · Diabetes · doi:10.2337/db09-1732 · Cited by 77
“, it will also be critical to test whether the new breed of recently developed specific SIRT1 activators (22,23), which do not directly activate AMPK, have a requirement for AMPK in mediating their metabolic and insulin-sensitizing effects.”
BackgroundThe emerging role of lysine acetylation of non-nuclear proteins
Close, P., Creppe, C., Gillard, M., Ladang, A., Chapelle, J.-P., Nguyen, L., & Chariot, A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0252-7 · Cited by 89
“These conclusions were further supported by the ability of small molecule activators of SIRT1 to improve symptomatic conditions in diet and genetically induced obese mice and in a rat model of diabetes [43].”
BackgroundGhisays, F., Brace, C. S., Yackly, S. M., Kwon, H. J., Mills, K. F., Kashentseva, E. A., Dmitriev, I. P., Curiel, D. T., Imai, S., & Ellenberger, T. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.036 · Cited by 84
“SIRT1 also has a large, N-terminally flanking domain that interacts with AROS (Kim et al., 2007b), the active regulator of SIRT1, as well as small molecule activators of deacetylase activity (Milne et al., 2007).”
BackgroundInfluentialAshrafizadeh, M., Rafiei, H., Mohammadinejad, R., Farkhondeh, T., & Samarghandian, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01773-7 · Cited by 80
Khader, A., Yang, W.-L., Kuncewitch, M., Jacob, A., Prince, J. M., Asirvatham, J. R., Nicastro, J. M., Coppa, G. F., & Wang, P. (2014) · Transplantation · doi:10.1097/tp.0000000000000194 · Cited by 79
“SRT1720 is a small molecule activator of Sirt1, which allosterically increases its affinity to acetylated protein substrates (25).”
BackgroundMethodMaeda, S., Koya, D., Araki, S., Babazono, T., Umezono, T., Toyoda, M., Kawai, K., Imanishi, M., Uzu, T., Suzuki, D., et al. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0418-0 · Cited by 76
“SIRT1 activation is considered to be a key mediator for favorable effects on lifespan or on metabolic activity in animals under calorie restriction (CR) [21–24].”
BackgroundFarghali, H., Canová, N. K., & Lekić, N. (2013) · Physiological Research · doi:10.33549/physiolres.932434 · Cited by 81
Takashina, M., Inoue, S., Tomihara, K., Tomita, K., Hattori, K., Zhao, Q., Suzuki, T., Noguchi, M., Ohashi, W., & Hattori, Y. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3859 · Cited by 76
“However, the presence of the AMPK inhibitor compound C (5 µM) failed to negate the anti-viability effect of resveratrol observed in U937, MOLT-4, MCF-7, and HepG2.”
InfluentialDihingia, A., Ozah, D., Ghosh, S., Sarkar, A., Baruah, P. K., Kalita, J., Sil, P. C., & Manna, P. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.09.022 · Cited by 78
Chen, H., Ji, H., Zhang, M., Liu, Z., Lao, L., Deng, C., Chen, J., & Zhong, G. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3046-16.2017 · Cited by 79
“Previous studies have also demonstrated that SIRT1 regulates inflammatory cytokine production by deacetylating the Lys310 residue of RelA/p65 (Zhu et al., 2011; Moon et al., 2013).”
BackgroundAging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis
Zhang, X., He, S., Liang, X., Li, W., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728100 · Cited by 88
Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes
Imai, S.-I. (2009) · Frontiers in Bioscience · doi:10.2741/3428 · Cited by 75
“have shown that new small molecule activators of SIRT1, which are structurally unrelated to and 1,000-fold more potent than resveratrol, improve insulin sensitivity, lower plasma glucose, and increase mitochondrial function in diet-induced obese and genetically obese mice (54).”
Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress
Melhem, H., Hansmannel, F., Bressenot, A., Battaglia-Hsu, S.-F., Billioud, V., Alberto, J., Guéant, J., & Peyrin‐Biroulet, L. (2015) · Gut · doi:10.1136/gutjnl-2014-307030 · Cited by 78
Nguyen, G. T. T., Gertz, M., & Steegborn, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.019 · Cited by 81
Function and regulation of the mitochondrial Sirtuin isoform Sirt5 in Mammalia
Gertz, M., & Steegborn, C. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.011 · Cited by 82
SIRT7 Is Activated by DNA and Deacetylates Histone H3 in the Chromatin Context
Tong, Z., Wang, Y., Zhang, X., Kim, D. D., Sadhukhan, S., Hao, Q., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01084 · Cited by 75
“The open reading frames of full length human SIRT7 (1-400), ΔN (56-400), ΔC (1-364), and the core domain (56-364) were inserted into the pET28a vector.”
MethodYoungson, N. A., Morris, M. J., & Ballard, J. W. O. (2017) · Seizure · doi:10.1016/j.seizure.2017.09.005 · Cited by 85
Bartoli‐Leonard, F., Wilkinson, F. L., Schiro, A., Serracino‐Inglott, F., Alexander, M. Y., & Weston, R. (2019) · Scientific Reports · doi:10.1038/s41598-018-37027-2 · Cited by 82
SIRT1 Modulation as a Novel Approach to the Treatment of Diseases of Aging
Blum, C. A., Ellis, J. L., Loh, C., Ng, P. Y., Perni, R. B., & Stein, R. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100861p · Cited by 73
Self-citationSpatial dynamics of SIRT1 and the subnuclear distribution of NADH species
Aguilar‐Arnal, L., Ranjit, S., Stringari, C., Orozco-Solís, R., Gratton, E., & Sassone‐Corsi, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609227113 · Cited by 80
“Because the diffusion coefficient of free nuclear EGFP is >10 μm(2)/s (our measurements) (50, 51), the slow mobility displayed by SIRT1-EGFP at specific locations is presumably linked to its interaction with substrates or to the coenzyme NAD.”
BackgroundEffects of Ginsenoside Rg3 on fatigue resistance and SIRT1 in aged rats
Yang, Q., Lai, X., Ouyang, J., & Yang, J. (2018) · Toxicology · doi:10.1016/j.tox.2018.08.010 · Cited by 78
Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction
Kalliora, C., Kyriazis, I. D., Oka, S., Lieu, M., Yue, Y., Área-Gómez, E., Pol, C. J., Tian, Y., Mizushima, W., Chin, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129556 · Cited by 91
“Future studies that will use more SIRT1 activators, such as metformin (70, 71) and SRT1720 (72), are warranted in order to elucidate further to elucidate further the interplay among fatty acid oxidation, altered NAD+:NADH ratio, SIRT1, SIRT3, and acetyl-transferases, such as GCN5 (73), in regulating acetylation and ac…”
BackgroundRenaud, J., Bournival, J., Zottig, X., & Martinoli, M. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9439-7 · Cited by 77
“…potential in defending neurons against oxidative assaults induced by a spectrum of treatments, including neurotoxins (Gélinas and Martinoli 2002; Blanchet et al. 2008; Bournival et al. 2009; Peritore et al. 2012; Wu et al. 2012) or cerebral ischemic injury (Morris et al. 2011; Simão et al. 2012).”
BackgroundSirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection
Kakefuda, K., Fujita, Y., Oyagi, A., Hyakkoku, K., Kojima, T., Umemura, K., Tsuruma, K., Shimazawa, M., Ito, M., Nozawa, Y., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.119 · Cited by 75
Khan, R. S., Dine, K. E., Sarma, J. D., & Shindler, K. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-3 · Cited by 78
“The dose was chosen based on previously measured pharmacokinetics of the drug and its ability to activate SIRT1 which has been used previously with maximal effects [27,33,34].”
Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model
Gabay, O., Sanchez, C., Dvir‐Ginzberg, M., Gagarina, V., Zaal, K. J. M., Song, Y., He, X. H., & McBurney, M. W. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37750 · Cited by 76
“Three SIRT-1–activating molecules have been identified and studied in the treatment of diabetes in mice (33) and may show promise in retarding cartilage destruction in OA.”
BackgroundArtsi, H., Cohen-Kfir, E., Gurt, I., Shahar, R., Bajayo, A., Kalish, N., Bellido, T. M., Gabet, Y., & Dresner-Pollak, R. (2014) · Endocrinology · doi:10.1210/en.2014-1334 · Cited by 73
Mouchiroud, L., Molin, L., Dallière, N., & Solari, F. (2010) · BioFactors · doi:10.1002/biof.127 · Cited by 73
“Regarding obesity, other sirtuins activators have also shown similar protection in mice, suggesting that this effect of reveratrol is likely mediated by sirtuins [29].”
BackgroundZamora‐Ros, R., Urpí-Sardà, M., Lamuela-Raventós, R. M., Martínez‐González, M. Á., Salas‐Salvadó, J., Arós, F., Fitó, M., Lapetra, J., Estruch, R., & Andrés‐Lacueva, C. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.03.009 · Cited by 85
Cameron, R. B., Beeson, C., & Schnellmann, R. G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00669 · Cited by 84
Kulkarni, S. R., Soroka, C. J., Hagey, L. R., & Boyer, J. L. (2016) · Hepatology · doi:10.1002/hep.28826 · Cited by 75
“SRT1720 is an agonist of Sirt1 that binds at an allosteric site, positioned at N-terminal with respect to the catalytic domain of the protein, and lowers the Michaelis-Menten constant for acetylated substrates.((45,46)) At the same time, SRT1720 also induces SUMOylation of Sirt1 in vivo that is associated with Sirt1 p…”
BackgroundClinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus
Sommese, L., Zullo, A., Mancini, F. P., Fabbricini, R., Soricelli, A., & Napoli, C. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278097 · Cited by 80
“As result, authors found that the regulation of cell proliferation is the most common process associated to T2DM.”
BackgroundInfluentialActivation and overexpression of Sirt1 attenuates lung fibrosis via P300
Zeng, Z., Cheng, S., Chen, H., Li, Q., Hu, Y., Wang, Q., Zhu, X., & Wang, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.155 · Cited by 79
Caloric restriction and exercise “mimetics”: ready for prime time
Handschin, C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.009 · Cited by 72
“Similarly, the direct activation of other pharmacological SIRT1 modulators [42] has likewise been questioned, for example that of SRT1720 [40].”
BackgroundSIRT1: Harnessing multiple pathways to hinder NAFLD
Tian, C., Huang, R., & Xiang, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107155 · Cited by 89
Tsukihara, S., Akiyama, Y., Shimada, S., Hatano, M., Igarashi, Y., Taniai, T., Tanji, Y., Kodera, K., Yasukawa, K., Umeura, K., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03243-6 · Cited by 93
“Resveratrol-related SIRT1 activators, such as SRT1720, SRT2104, SRT2379, and SRT3205, have been developed [61].”
Emerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
Resveratrol Possesses Protective Effects in a Pristane-Induced Lupus Mouse Model
Wang, Z., Luo, X., Li, M., Xu, D., Zhou, S., Chen, H., Gao, N., Chen, Z., Zhang, L., & Zeng, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114792 · Cited by 72
“Moreover, studies have shown that resveratrol can inhibit several experimental autoimmune diseases, including collagen-induced arthritis, encephalomyelitis, colitis, and diabetes, though the mechanisms are not fully understood [16, 17, 18, 19, 20].”
BackgroundThe role of sirtuins in Alzheimer's disease
Lalla, R., & Donmez, G. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00016 · Cited by 72
Bastin, J., Lopes-Costa, A., & Djouadi, F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr089 · Cited by 72
Midlife gene expressions identify modulators of aging through dietary interventions
Zhou, B., Yang, L., Li, S., Huang, J., Chen, H., Hou, L., Wang, J., Green, C. D., Yan, Z., Huang, X., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119304109 · Cited by 71
Using mitochondrial sirtuins as drug targets: disease implications and available compounds
Gertz, M., & Steegborn, C. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2180-7 · Cited by 80
“2), but other compound classes were described subsequently [12, 193]—can extend lifespan in various species and have beneficial effects in mammals such as promotion of cell survival and protection against insulin resistance [8].”
BackgroundInfluentialNeuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence
Romeo-Guitart, D., Forés, J., Herrando-Grabulosa, M., Valls, R., Leiva-Rodríguez, T., Galea, E., González-Pérez, F., Navarro, X., Petegnief, V., Bosch, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19767-3 · Cited by 71
“This is an interesting discovery because SIRT1 activators have long been sought due to the beneficial effects likely for several diseases 52–54 .”
BackgroundMitochondria as target of endocrine-disrupting chemicals: implications for type 2 diabetes
Marroquí, L., Tudurí, E., Alonso‐Magdalena, P., Quesada, I., Nadal, Á., & dos Santos, R. S. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0362 · Cited by 77
Buhrmann, C., Yazdi, M., Popper, B., Kunnumakkara, A. B., Aggarwal, B. B., & Shakibaei, M. (2019) · Nutrients · doi:10.3390/nu11030704 · Cited by 75
“Interestingly, it has been shown previously, that the subcellular main target Sirt-1 protein for resveratrol is associated with NF-κB, and that Sirt-1 is able to deacetylate NF-κB on lysine 310, thus modulating NF-κB transcriptional activity [54,65].”
BackgroundKosgei, V. J., Coelho, D., Guéant‐Rodriguez, R., & Guéant, J. (2020) · Cells · doi:10.3390/cells9081882 · Cited by 79
“SRT1720 and resveratrol improve insulin sensitivity in nutritionally and genetically induced obesity and DT2 in mice [125].”
Liu, Y., Liu, N., Wang, A., Chen, N., & Li, S. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521000544 · Cited by 74
“NAD-dependent protein deacetylase, can efficiently lower plasma glucose content and improve insulin sensitivity in diabetes model (15-17) , and this makes SIRT1 activation”
Acetylation and deacetylation—novel factors in muscle wasting
Alamdari, N., Aversa, Z., Castillero, E., & Hasselgren, P.-O. (2013) · Metabolism · doi:10.1016/j.metabol.2012.03.019 · Cited by 71
“[71] Milne JC, Lambert PD, Schenk S, et al.”
MethodPromise of resveratrol for easing status epilepticus and epilepsy
Shetty, A. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.008 · Cited by 80
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript al., 2004; Milne et al., 2007; Rajendrasozhan et al., 2008; Chung et al., 2010; Singh et al., 2010).”
BackgroundSulforaphane induces adipocyte browning and promotes glucose and lipid utilization
Zhang, H. Q., Chen, S. Y., Wang, A. S., Yao, A.-J., Fu, J. F., Zhao, J., Chen, F., Zou, Z., Zhang, X. H., Shan, Y. J., et al. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500915 · Cited by 78
“Sirt-1, an NAD+-dependent protein deacetylase, has emerged as an important metabolic sensor, and its activation by small molecules, calorie restriction, or exercise promotes mitochondrial biogenesis and activities [18, 19].”
BackgroundGenetic Control of Fatty Acid β-Oxidation in Chronic Obstructive Pulmonary Disease
Jiang, Z., Knudsen, N. H., Wang, G., Qiu, W., Naing, Z. Z. C., Bai, Y., Ai, X., Lee, C., & Zhou, X. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0282oc · Cited by 74
Srivastava, S., & C. Haigis, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072526 · Cited by 70
Silent information regulator, Sirtuin 1, and age‐related diseases
Zeng, L., Chen, R., Liang, F.-X., Tsuchiya, H., Murai, H., Nakahashi, T., Iwai, K., Takahashi, T., Kanda, T., & Morimoto, S. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2008.00504.x · Cited by 73
Yang, J., Yeh, H.-Y., Lin, K., & Wang, P. H. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.02.015 · Cited by 77
“Diet-induced Type 2 diabetes such as HFF model is associated with insulin resistance whereas STZ-DM features enhanced insulin receptor signaling to PI3K/Akt pathway [21,22,24].”
Human Sirt-1: Molecular Modeling and Structure-Function Relationships of an Unordered Protein
Autiero, I., Costantini, S., & Colonna, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007350 · Cited by 81
“We found that AROS binds the same allosteric site of some small synthetic compounds (not shown; manuscript in preparation) proposed as putative therapeutics for the treatment of type 2 diabetes [2,19].”
BackgroundBecatti, M., Fiorillo, C., Barygina, V. V., Cecchi, C., Lotti, T., Prignano, F., Silvestro, A., Nassi, P., & Taddei, N. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12206 · Cited by 71
“Many of the cellular processes regulated by Akt are also modulated by SIRT1: indeed, SIRT1 has been used to treat metabolic disorders characterized by aberrant Akt signalling [66].”
BackgroundKuryłowicz, A., Owczarz, M., Połosak, J., Jonas, M. I., Lisik, W., Jonas, M., Chmura, A., & Puzianowska‐Kuźnicka, M. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.131 · Cited by 71
SIRT1 is a positive regulator of the master osteoblast transcription factor, RUNX2
Zainabadi, K., Liu, C. J., & Guarente, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178520 · Cited by 75
Research progress on Sirtuins (SIRTs) family modulators
Chen, M., Tan, J., Jin, Z., Jiang, T., Wu, J., & Yu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116481 · Cited by 80
Saunders, L. R., & Verdin, E. M. (2009) · Science · doi:10.1126/science.1170007 · Cited by 78
Natural products in diabetes research: quantitative literature analysis
Yeung, A. W. K., Tzvetkov, N. T., Durazzo, A., Lucarini, M., Souto, E. B., Santini, A., Gan, R., Jóźwik, A., Grzybek, W., Horbańczuk, J. O., et al. (2020) · Natural Product Research · doi:10.1080/14786419.2020.1821019 · Cited by 75
Effect of resveratrol on endothelial cell function: Molecular mechanisms
Schmitt, C. A., Heiß, E. H., & Dirsch, V. M. (2010) · BioFactors · doi:10.1002/biof.109 · Cited by 82
“These findings underline the protective effect of SIRT1 against diabetes-related vascular complications [64].”
BackgroundMitochondrial involvement in skeletal muscle insulin resistance: A case of imbalanced bioenergetics
Affourtit, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.07.008 · Cited by 67
Bao, J., & Sack, M. N. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0402-y · Cited by 67
“These compounds have been shown to bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates [20].”
Costa‐Machado, L. F., & Fernández-Marcos, P. J. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1634953 · Cited by 69
“In fact, several reports have shown that some of the most widely used sirtuin activators (resveratrol, SRT1720, SRT2183 or SRT1460) are actually not direct SIRT1 activators, displaying offtarget effects that had not been extensively studied [304,305].”
BackgroundInfluentialKang, H., & Kim, B. (2023) · Foods · doi:10.3390/foods12050925 · Cited by 86
“The post-translational deacetylation by SIRT1 has been controlled in response to cellular stresses [23,47], including excessive alcohol, high-fat, or high-glycemic diet.”
BackgroundInfluentialInsulin signaling and life span
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2009) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0721-8 · Cited by 75
“Indeed, in Zucker fa/fa rats, Sirt1 activation improved whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle, and liver [ 85 ].”
BackgroundNovel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes
Saberi, M., Bjelica, D., Schenk, S., Imamura, T., Bandyopadhyay, G. K., Li, P., Jadhar, V., Vargeese, C., Wang, W., Bowman, K., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00158.2009 · Cited by 69
“For the rats studies the siCON and siTORC2 was administered iv via a chronically cannulated jugular vein, as previously described (21).”
MethodSelf-citationGeroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease
Ito, K., Colley, J. R., & Mercado, N. (2012) · International Journal of COPD · doi:10.2147/copd.s28250 · Cited by 73
“Recently a SIRT1-specific activator that is 1000 more potent than resveratrol has been developed and examined as a possibile therapy for diabetics.(98) SRT2172 is one of the potent sirtuin activators.”
Nguyen, G. T. T., Schaefer, S., Gertz, M., Weyand, M., & Steegborn, C. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913015448 · Cited by 79
“In contrast to the potent inhibition observed for Sirt3 (Jin, Galonek et al., 2009, and this study), Sirt2 and Sirt5 are only very weakly inhibited (Milne et al., 2007; Suenkel et al., 2013).”
BackgroundResultInfluentialTherapeutic targets of hypercholesterolemia: HMGCR and LDLR
Ma, S., Sun, W., Gao, L., & Liu, S. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s219013 · Cited by 80
“SREBP pathway, which suggests that SREBP may be a new drug target in the future.(60,61) Ring finger protein 145”
Background
Metadata
- Authors
- Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J., & Westphal, C. H.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Westphal, Christoph H.
- ORCID
- Venue
- Nature
- Published
- 2007-11-29
- Volume
- 450
- Issue
- 7170
- Pages
- 712-716
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2753457
- OpenAlex
- W2116350182
- Cited by
- 1,707
- References
- 27
- Citations by year
- 2026: 38 · 2025: 43 · 2024: 55 · 2023: 55 · 2022: 68 · 2021: 100 · 2020: 80 · 2019: 75 · 2018: 82 · 2017: 69 · 2016: 92 · 2015: 89 · 2014: 110 · 2013: 119 · 2012: 126
- FWCI
- 55.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (P01AG027916, R01AG028730, R01AG019719)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- SIRT1, small molecule activators, type 2 diabetes, insulin resistance, caloric restriction mimetics, resveratrol, NAD+-dependent deacetylase, allosteric site, glucose homeostasis, mitochondrial function, obesity, aging, drug screening
- MeSH terms
- Resveratrol, Acetylation, Allosteric Site, Animals, Blood Glucose, Cell Line, Diabetes Mellitus, Type 2, Dietary Fats, Disease Models, Animal, Drosophila melanogaster, Heterocyclic Compounds, 4 or More Rings, Humans, Insulin, Male, Mitochondria, Rats, Zucker, Stilbenes, Rats, Sprague-Dawley, Catalytic Domain, Caloric Restriction, Sirtuins, Mice, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.